Találati lista | Tudóstér

001-es BibID:	BIBFORM081584
Első szerző:	Zrubka Zsombor
Cím:	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis : systematic review and meta-analysis / Zrubka Zsombor, Gulácsi László, Brodszky Valentin, Rencz Fanni, Alten Rieke, Szekanecz Zoltán, Péntek Márta
Dátum:	2019
ISSN:	1473-7167 1744-8379
Megjegyzések:	Introduction: Early biological treatment of rheumatoid arthritis (RA) may reverse the autoimmune response in some patients resulting in favorable long-term outcomes. Although the cost-effectiveness of this strategy has been questioned, biosimilar entries warrant the revision of clinical and pharmaco-economic evidence. Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) published up to 24 May 2018 in Pubmed, EMBASE and Cochrane CENTRAL, comparing infliximab with non-biological therapy in patients with RA naïve to methotrexate. We performed meta-analyses for efficacy outcomes at month 6 and years 1 and 2. Six RCTs were identified, involving 1832 patients. At month 6 ACR70 response and remission, and at year 1 ACR20/ACR70 responses and remission were improved significantly with first-line infliximab versus control. The differences were not significant at year 2. We reviewed cost-utility studies, up to 31 October 2018 in PubMed, Cochrane CENTRAL and the CRD HTA databases. Four studies indicated that first-line use of originator infliximab calculated at 2005?2008 prices was not cost-effective. Expert opinion: We demonstrated the efficacy benefits of first-line infliximab therapy up to 1 year in methotrexate-naïve RA. We highlighted the need for standardized reporting of outcomes and conducting cost-effectiveness analyses of first-line biosimilar therapy in RA.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Biosimilar cost-utility analysis efficacy infliximab meta-analysis early rheumatoid arthritis
Megjelenés:	Expert Review of Pharmacoeconomics & Outcomes Research. - 19 : 5 (2019), p. 537-549. -
További szerzők:	Gulácsi László Brodszky Valentin Rencz Fanni Alten, Rieke Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Péntek Márta
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: